Leukemia Research
Volume 28, Issue 10 , Pages 1007-1011 , October 2004

Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome

  • Hong Chang

      Affiliations

    • Department of Laboratory Hematology, Princess Margaret Hospital, University Health Network, 610 University Ave., 4-320, Toronto, ON, Canada M50 2M9
    • Corresponding Author InformationCorresponding author. Tel.: +1-416-946-4635; fax: +1-416-946-4616.
    • ,
  • Joseph Brandwein

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
    • ,
  • Qi-Long yi

      Affiliations

    • Department of Biostatistics, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
    • ,
  • Kathy Chun

      Affiliations

    • Department of Pathology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
    • ,
  • Bruce Patterson

      Affiliations

    • Department of Laboratory Hematology, Princess Margaret Hospital, University Health Network, 610 University Ave., 4-320, Toronto, ON, Canada M50 2M9
    • ,
  • Bill Brien

      Affiliations

    • Department of Laboratory Hematology, Princess Margaret Hospital, University Health Network, 610 University Ave., 4-320, Toronto, ON, Canada M50 2M9
    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada

Received 11 September 2003 ,Accepted 16 January 2004.

References 

  1. Byrd JC, Edenfield WJ, Shields DJ, Dawson NA. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J. Clin. Oncol. 1995;13:1800–1816
  2. Grier HE, Gelber RD, Camitta BM, Delorey MJ, Link MP, Price KN, et al.  Prognostic factors in childhood acute myelogenous leukemia. J. Clin. Oncol. 1987;5:1026–1032
  3. Ravindranath Y, Steuber CP, Krischner J, Civin CI, Ducore J, Vega R, et al.  High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. J. Clin. Oncol. 1991;9:572–580
  4. Gehan EA, Smith TL, Freireich EJ, Bodey G, Rodriguez V, Speer J, et al.  Prognostic factors in acute leukemia. Semin. Oncol. 1976;3:271–282
  5. Woods WG, Kobrinsky N, Buckley J, Neudorf S, Sanders J, Miller L, et al.  Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplatic syndrome: A Childrens Cancer Group pilot study. J. Clin. Oncol. 1993;11:1448–1457
  6. Tallman MS, Hakimian D, Shaw JM, Lissner GJ, Russel EJ, Variakojis D. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J. Clin. Oncol. 1993;4:690–697
  7. Byrd JC, Weiss RB, Arthur DC, Lawrence D, Baer MR, Davey F, et al.  Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21) (q22;q22): Results from cancer and leukemia group B8461. J. Clin. Oncol. 1997;15:466–475
  8. Amadori S, Testi AM, Arico M, Comelli A, Giuliano M, Madon E, et al.  Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J. Clin. Oncol. 1993;11:1046–1054
  9. Lizuka Y, Aiso M, Oshimi K, Kanemarn M, Kawamura M, Takeuchi J, et al.  Myeloblastoma formation in acute myeloid leukemia. Leuk. Res. 1992;16:665–671
  10. Seymour JF, Pierce SA, Kantrajian HM, Keating MJ, Estey EH. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia. 1994;8:823–826
  11. Mitelman F, editor, ISCN: An International System for Human Cytogenetic Nomenclature. Basel: Karger S, 1995.
  12. Kaplan EL, Meier P. Non parametric estimation for incomplete observations. J. Am. Stat. Assoc. 1958;53:457–481
  13. SAS Institute. Additional SAS/STAT Procedures. SAS Technical Report. Cary. NC: SAS Institute 1988, p. 179.
  14. Jenkin RD, Al-Shabanah M, Al-Nasser A, El-Solh H, Al Sudairy R, Mustafa MM, et al.  Extramedullary myeloid tumors in children: the limited value of local treatment. J. Pediatr. Hematol. Oncol. 2000;22:34–40
  15. Creutzig U, Harbott J, Sperling C, Riffer J, Zimmermann M, Löffier H, et al.  Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood. 1995;86:3097–3108
  16. Rubnitz JE, Raimondi SC, Halbert AR, Tong X, Srivastava DK, Razzouk BI, et al.  Characteristics and outcome of t(821) positive childhood acute myeloid leukemia: a single institution’s experience. Leukemia. 2002;16:2072–2077
  17. Byrd JC, Weiss RB. Recurrent granulocytic sarcoma: an unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule. Cancer. 1994;73:2107–2112
  18. Schwyzer R, Sherman GG, Cohn RJ, Poole JE, Willem P. Granulocytic sarcoma in children with acute myeloblastic leukemia and t(8;21). Med. Pediatr. Oncol. 1998;31:144–149
  19. Rubnitz JE, Behm FG, Downing JR. 11q23 rearrangements in acute leukemia. Leukemia. 1996;10:74–82
  20. Broeker PLS, Super HG, Thirman MJ, Pomykala H, Yonebayashi Y, Tanabe S, et al.  Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia. Correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood. 1996;87:1912–1922
  21. Cimino G, Rapanotti MC, Elia L, Biondi A, Fizzotti M, Testi AM, et al.  ALL-1 gene rearrangements in acute myeloid leukemia: association with M4-M5 French-American-British classification subtypes and young age. Cancer Res. 1995;55:1625–1628
  22. Hercend T, Griffin JD, Bensussan A, Schmidt RE, Edson MA, Brennan A, et al.  Generation of monoclonal antibodies to a human natural killer clone: characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J. Clin. Invest. 1985;75:932–943
  23. Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J. Exp. Med. 1989;169:2233–2238
  24. Zocchi MR, Vidal M, Poggi A. Involvement of CD56/N-CAM molecule in the adhesion of human solid tumor cell lines to endothelial cells. Exp. Cell Res. 1993;204:130–135
  25. Wong KF, Chan JKC, Ng CS, Tsang WYW. CD56 (NKH1)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity. Hum. Pathol. 1992;23:798–804
  26. Kern WF, Spier CM, Hanneman EH, Miller TP, Matzner M, Grogan TM. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood. 1992;79:2432–2437
  27. Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, et al.  Expression of the neural cell adhesion molecular CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood. 1997;90:1643–1648

PII: S0145-2126(04)00037-2

doi: 10.1016/j.leukres.2004.01.006

Leukemia Research
Volume 28, Issue 10 , Pages 1007-1011 , October 2004

Article Tools

* Image Usage & Resolution